Adult Liver Transplant Recipient Registration Worksheet

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI® application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI® application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information		
Name:	DO	
SSN:		th sex:
HIC:		ensplant Date and ne:
State of Permanent Residence: *		
Permanent Zip: *	-	
Provider Information		
Recipient Center:		
Surgeon Name: *		
NPI#:*		
Donor Information		
UNOS Donor ID #:		
Recovering OPO:		
Donor Type:		
Patient Status		
Primary Diagnosis: *		
Specify:		
Date: Last Seen, Retransplanted or Death*		
Patient Status: *	CLIVING	
	ODEAD	
	RETRANSPLANTED	
Primary Cause of Death:		
Specify:		
Contributory Cause of Death:		
Specify:		
Contributory Cause of Death:		·
Specify:		
Transplant Hospitalization: Date of Admission to Tx Center: *		
Date of Discharge from Tx Center:		
Clinical Information : PRETRANSPLANT		
Medical Condition at time of transplant: *	OIN INTENSIVE CARE	TINU
	HOSPITALIZED NOT	IN ICU
	ONOT HOSPITALIZED	
Patient on Life Support: *	OYES ONO	
	☐ Ventilator	
	Artificial Liver	
Specify:	Other Mechanism, Speci	fy
Functional Status: *	00	
Working for income:*	YES NO UNK	
Source of Payment:		
Copyright © 2023 United Network for C	organ Sharing. All rights	reserved. OPTN use only. 091423

Primary: *			
Specify:			
eight: *	ft. in.	cm	ST=
eight: *	lbs	kg	ST=
II:	kg/m ²		
evious Transplants:			
-	Previous Transplant Date	Previous Transplant G	Graft Fail Date
evious Transplant Organ	Frevious Transplant Date	rievious transplant o	nait i an Date
ne three most recent transplants are listed here.	Please contact the UNet Help Desk to confirm	m more than three previous t	transplants by calling 800-978-4334 or
nailing unethelpdesk@unos.org.			
ral Detection:			
HIV Serostatus: *	Positive		
	ONegative		
	Not Done		
	OUNK/Cannot Disclose		
		=	
CMV Status*	Positive		
	Negative		
	Not Done		
	UNK/Cannot Disclose	e	
HBV Surface Antibody Total ∗	Positive		
	Negative		
	Not Done		
	OUNK/Cannot Disclose	e	
HBV Core Antibody: ∗	Positive		
,	Negative		
	Not Done		
		_	
	OUNK/Cannot Disclose	=	
HBV Surface Antigen: ★	Positive		
	Negative		
	Not Done		
	OUNK/Cannot Disclose	e	
HCV Serostatus:∗	Positive		
	Negative		
	Not Done		
	OUNK/Cannot Disclose	e	
EBV Serostatus: *	Positive		
	ONegative		
	Not Done		
		_	
	OUNK/Cannot Disclose	=	
accination Status:			
Did the recipient receive Hepatitis B vaccines p transplant?: *	rior to YES NO UNK		
Reason not vaccinated:	○ Immunity		
	Medical precaution		
	Time constraints		
	Patient objection		
	Product out of stock		
	Other, specify		
	outer, specify		

NAT Results:	
HIV NAT:∗	Positive
	Negative
	Not Done
	UNK/Cannot Disclose
HBV NAT: ∗	Positive
	ON Negative
	Not Done
	UNK/Cannot Disclose
HCV NAT: *	Positive
164 1641.76	Negative
	Not Done
	UNK/Cannot Disclose
	ONK/ Calliot Disclose
Has the recipient ever had a diagnosis of HCC?* OYES	DNO DNO
Clinical Information : TRANSPLANT PROCEI	DURE
Multiple Organ Recipient	
Were extra vessels used in the transplant procedure:	
Procedure Type:	Whole Liver
	Partial Liver, remainder not Tx or Living Transplant
	Split Liver
	Whole Liver with Pancreas (Technical Reasons)
	Partial Liver with Pancreas (Technical Reasons)
	Split Liver with Pancreas (Technical Reasons)
Split Type:	
Preservation Information:	
Total Cold Ischemia Time (if pumped, include pump time):	hrs ST=
Risk Factors:	
Previous Abdominal Surgery: *	YES NO UNK
Portal Vein Thrombosis: *	○YES ○NO ○UNK
Transjugular Intrahepatic Portosystemic Shunt:*	YES NO UNK
Organ Check-in Information:	
Liver Check-In Date: Time:	Military time Time Zone: ST=
Clinical Information : POST TRANSPLANT	
Pathology Conf. Liver Diag. of Hospital Discharge: *	
Specify:	
Graft Status: *	Functioning Failed
If death is indicated for the recipient, and the death was a result of	of some other factor unrelated to graft failure, select Functioning.
Copyright © 2023 United Network for Org	gan Sharing. All rights reserved. OPTN use only. 091423

Date of Graft Failure:						
Causes of graft failure:						
Primary Non Function	YES NO UNK					
Hepatic Artery Thrombosis	OYES ONO OUNK					
Other Vascular Thrombosis	YES NO UNK					
Diffuse Cholangiopathy	YES NO UNK					
Hepatitis: DeNovo	YES NO UNK					
Hepatitis: Recurrent	YES NO UNK					
Recurrent Disease (non-Hepatitis)	OYES ONO OUNK					
Acute Rejection	OYES ONO OUNK					
Infection	YES NO UNK					
Other, Specify:						
Did patient have any acute rejection episodes between transplant and discharge: *	Yes, at least one of Yes, none treated No		_	_		
Immunosuppressive Information Are any medications given currently for maintenance or anti-rejection: *	YES NO					
Immunosuppressive Medications						
View Immunosuppressive Medications						
For each of the immunosuppressive medications listed, select Ind prescribed for the recipient during the initial transplant hospitalizat Induction (Ind) immunosuppression includes all medications give Though the drugs may be continued after discharge for the first 30 Induction agents are usually polyclonal, monoclonal, or IL-2 recept drugs might be used for another finite period for rejection therapy medication indicated, write the total number of days the drug was apart then the total number of days would be 2, even if the second Maintenance (Maint) includes all immunosuppressive medication prednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azati rejection episodes, or for induction. Anti-rejection (AR) immunosuppression includes all immunosuppost-transplant period or during a specific follow-up period, usually Inhymoglobulin). When switching maintenance drugs (example: frothe drugs should not be listed under AR immunosuppression, but so If an immunosuppressive medication other than those listed is beir Immunosuppressive Medication field, and enter the full name of the	ion period, and for what ren for a short finite period of days after transplant, it or antibodies (example: n and would be recorded a actually administered in the dose was given after the finite period of the dose was given after the finite period of the dose was given after the finite period of the dose was given after the finite period of the dose was given at 30 days after the finite period of the dose was given at acrolimus to cyclospon the dose was given the dose was a finite period of the dose was after the dose was a finite period of the dose was a finite period of the dose was after the dose was a finite period of the dose was after the dose was a finite period of the dose was after the dose was a finite period of the dose was a finite period of the dose was given by the dose was a finite period of the dose was given and the dose was given at the dose	reason. If a medium the periop will not be use methylprednisos anti-rejection the space prove patient was deather transplatis does not in for the purpuliagnosis of actine; or from mintenance immy monoclonal at the proposition of the purpuliagnosis of actine; or from mintenance immy monoclonal at the proposition of the purpuliagnosis of actine; or from mintenance immy monoclonal at the proposition of the purpuling management of the purpulation of	erative period for id long-term for in lone, Campath, Ti n therapy if used fided. For example discharged. In the with the intenticulate any immunose of treating an ute rejection (example proposed for the monunosuppression. In antibodies), select	given, leave the the purpose of immunosuppression mymoglobulin, o or this reason. If if Simulect was on to maintain the osuppressive macute rejection mple: methylprefetil to azathiopi. Ind, Maint, or A.	associated box(es preventing acute reve maintenance. r Simulect). Some for each induction s given in 2 doses in them long-term (exedications given to episode during the admisolone, or rine) because of reach acute to Other) blank. ejection. of these a week xample: treat initial jection,
Drug used for induction, acute rejection, or	maintenance					
Steroids (prednisone, methylprednisolone, Solumedrol, Medrol)		Ind.	Days	ST	Maint	AR
Drugs used for induction or acute rejection						
		Ind.	Days	ST	Maint	AR
Atgam						
Campath (alemtuzumab)						
Cytoxan (cyclophosphamide)						
Methotrexate (Folex PFS, Mexate-AQ, Rheumatrex)						
Rituxan (rituximab)						
Simulect (basiliximab)						
Thymoglobulin						

Drugs primarily used for maintenance					
Gulanaria adatém ha fallania	Ind.	Days	ST	Maint	AR
Cyclosporine, select from the following:					
- Gengraf					
- Neoral					
- Sandimmune					
- Generic cyclosporine					
Imuran (azathioprine, AZA)					
Leflunomide (LFL)					
Mycophenolic acid, select from the following:					
- CellCept (MMF)					
- Generic MMF (generic CellCept)					
- Myfortic (mycophenolic acid)					
- Generic Myfortic (generic mycophenolic acid)					
mTOR inhibitors, select from the following:					
- Rapamune (sirolimus)					
- Generic sirolimus					
- Zortress (everolimus)					
Nulojix (belatacept)					
Tacrolimus, select from the following:					
- Astagraf XL (extended release tacrolimus)					
- Envarsus XR (tacrolimus XR)					
- Prograf (tacrolimus)					
- Generic tacrolimus (generic Prograf)					
Other drugs	Ind.	Dave	ST	Maint	AP
Other immunosuppressive medication, specify:	Ina.	Days	31	Маілт	AR
Other immunosuppressive medication, specify:					

Copyright © 2023 United Network for Organ Sharing. All rights reserved. Confidential - OPTN Use Only

UNOS Policies & Terms